PolyPid Ltd., una empresa farmacéutica en fase clínica, desarrolla, fabrica y comercializa productos basados en la plataforma de matriz de encapsulación polimérica-lipídica (PLEX) para dar respuesta a necesidades médicas no cubiertas. Su principal producto candidato es D-PLEX100, que ayuda a prevenir las infecciones quirúrgicas esternales (óseas), así como las abdominales (tejidos blandos). También está desarrollando OncoPLEX, para el tratamiento del cáncer intratumoral. PolyPid Ltd. se constituyó en 2008 y tiene su sede en Petah Tikva (Israel).
Nombre | Título | Desde | Edad |
|---|---|---|---|
| Brooke Elizabeth Story | Independent Non-Employee Chairman of the Board | 2025 | 55 |
| Dikla Czaczkes Akselbrad | CEO & Director | 2022 | 53 |
| Itzhak Krinsky | Independent Non-Employee Director | 2019 | 73 |
| Nir Dror | Independent Non-Employee Director | 2025 | 50 |
| Yechezkel Barenholz | Independent Non-Employee Director | 2008 | 84 |
| Yafit Stark | Clinical Development Strategy Advisor | 2008 | 71 |
| Noam Emanuel | Member of Scientific Advisory Board of Drug Delivery | 2024 | 67 |
| Moshe Salai | Member of Scientific Advisory Board | - | - |
| Erez Kachel | Member of Scientific Advisory Board | - | - |
| Hartzell V. Schaff | Member of Scientific Advisory Board | 2017 | - |
| Robert Benjamin Stein | Independent Non-Employee Director | 2020 | 75 |
| Frederick F. Lang | Member of Scientific Advisory Board | 2021 | - |
| Mitchel S. Berger | Member of Scientific Advisory Board | 2022 | 73 |
| Joseph BenAmram | Independent Non-Employee Director | 2023 | 61 |
| Raanan Berger | Member of Scientific Advisory Board of Oncology | 2024 | - |
| Yitzchak Jacobovitz | Independent Non-Employee Director | 2025 | 50 |